Literature DB >> 8959560

Reduced expression of dipeptidyl peptidase (DPP) IV in peripheral blood T lymphocytes of oral cancer patients.

T Uematsu1, M Urade, M Yamaoka, W Yoshioka.   

Abstract

To investigate the mechanism of decrease of serum DPP IV activity in oral cancer patients, we analyzed the expression of DPP IV in peripheral blood T lymphocytes of oral cancer patients and healthy subjects. Consequently, serum DPP IV activity was found to correlate significantly with the number of peripheral blood lymphocytes (PBL), T lymphocytes and CD26 (identified as DPP IV)+ T lymphocytes in healthy subjects, and the number of PBL and CD26+ T lymphocytes in cancer patients. However, the numbers of PBL and T lymphocytes were significantly less in cancer patients than in healthy subjects. Although the number of CD26+ T lymphocytes was somewhat greater in cancer patients than in healthy subjects, serum DPP IV activity was significantly lower in cancer patients. DPP IV activity and amount of CD26 in T lymphocyte plasma membranes were much less in cancer patients than in healthy subjects. These findings suggest that a decrease in the number of T lymphocytes and the small amount of DPP IV in their plasma membrane may contribute to the decrease of serum DPP IV activity in cancer patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8959560     DOI: 10.1111/j.1600-0714.1996.tb00306.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  2 in total

1.  Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer.

Authors:  O J Cordero; D Ayude; M Nogueira; F J Rodriguez-Berrocal; M P de la Cadena
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

2.  Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia.

Authors:  B Bauvois; I De Meester; J Dumont; D Rouillard; H X Zhao; E Bosmans
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.